Abstract
Aim: To measure serum myeloperoxidase (MPO) levels and to evaluate the relationship between this parameter and histological findings in chronic hepatitis B and C patients. Materials & methods: Three groups were formed: chronic hepatitis B, chronic hepatitis C and a control group. Serum MPO levels were determined by ELISA. Results: MPO level was found to be higher in both patient groups compared with the control group (p < 0.05). It was also higher in chronic hepatitis B and C patients with significant fibrosis compared with patients with mild fibrosis (p < 0.05). Conclusion: Our results show that increased MPO level can be used as an important noninvasive marker in both the early detection of liver fibrosis and the prediction of significant fibrosis.
Author contributions
Both authors made significant contributions to the concept or design of the work or the acquisition, analysis or interpretation of data; prepared and reviewed the work; provided final approval of the version to be published; and agree to be responsible for all aspects of the work to ensure that questions regarding the accuracy or completeness of any part are properly investigated and resolved.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The institutional review board of Fırat University (Elazig, Turkey) approved the study protocol (decision no. 34), and each participant was provided with a written informed consent form prior to the study. The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.